C-TLNEInsilico Medicine
generative AI, automation, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-TLNE
C-TLNEC-TLNEgenerative AI, automation, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients with advanced or metastatic solid tumors. The study will be conducted in 3 parts sequentially: Part 1 dose escalation ISM5939 monotherapy, Part 2 dose optimization to determine RP2D of ISM5939 monotherapy, and Part 3 dose expansion in 3 cohorts after initial safety run-in of ISM5939 combination therapy.
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969 in healthy adults and elderly participants and obese adult participants at risk of cardiovascular disease.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma
The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
The goal of this clinical trial is to learn about ISM5411 in healthy subjects. The primary objective is to evaluate the safety and tolerability of single and multiple oral doses of ISM5411 in healthy subjects.
Dive into the transformative world of AI and cloud computing as Google's technical director sheds light on the advancements in these technologies and their implications for longevity and disease research. Discover how cloud computing is revolutionizing research, the potential of AI in fields like computational chemistry, and the challenges and Join this channel to get access to perks: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q/join Newsletter sign up (new and exciting developments) https://learningwithlowell.us12.list-manage.com/subscribe?u=08ed8a56013d8b3a3c01e27fc&id=6ecaa9189b https://studio.youtube.com/video/LuOAShcjOt0/edit#:~:text=https%3A//youtu.be/LuOAShcjOt0 Over 321 books from 170 plus interviews over 5 years https://www.learningwithlowell.com/over-321-books-from-170-interviews-over-5-years-for-autodidacts/ PODCAST INFO: The Learning With Lowell show is a series for the everyday mammal. In this show we’ll learn about leadership, science, and people buildi
AI is rewriting drug discovery and longevity science — and Dr. Alex Zhavoronkov is one of the few people who has actually used it to put a generative-AI-discovered molecule into human clinical trials. In this episode of Health Longevity Secrets, Robert Lufkin MD and co-host Stephen Sideroff PhD sit down with Dr. Alex Zhavoronkov, founder of Insilico Medicine and Deep Longevity, to unpack how deep neural networks are accelerating target discovery, generating novel small molecules, and predicting biological age from blood, methylation, images, and even psychology. CHAPTERS: 00:00 — Introduction: AI Is Transforming Longevity 01:01 — Alex Zhavoronkov's Path: From Semiconductors to Aging 04:06 — Insilico Medicine: AI Target Discovery from Gene Expression 05:06 — PandaOmics: AI for Disease and Aging Target Discovery 06:06 — Chemistry42: Generative AI for Small Molecule Drug Design 07:07 — Why Insilico Went After Fibrosis and IPF First 09:09 — From AI Target to Phase 1 Human Clinical Trial
The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018\_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose \[SAD\]) and Part B (multiple ascending dose \[MAD\]).
To read more about the discovery: https://insilico.com/blog/pcc Dr. Charles Cantor Professor Emeritus at Boston University, Co-Founder of Sequenom Inc., Co-Founder of Retrotope Inc. Former Principal Scientist of Human Genome Project, Department of Energy, Co-founder of Sequenom (acquired by LabCorp), Professor and Director of the Center for Advanced Biotechnology, Boston University
Unlocking AI KPIs With Insilico | TD Securities Skip to main content Careers Search Search Bookmarks Find Us Canada Japan English en_CA English Français Login One Portal Global Strategy Equity Research TD Liquidity Manager Prime Brokerage Structured Notes TDfacilitrade TDFX WebBroker TD Prime Services About Us Overview Awards Deals Diversity & Inclusion Leadership History Newsroom Insights All Insights Viewpoint Podcast Buyside Views Bid Out Podcast Geopolitics Podcast TD Cowen Insights Podcast Services Corporate & Investment Banking Global Markets Global Transaction Banking Research & Strateg … a lot of money. Those are called IND-enabling studies, investigational new drug application studies. That require you to go for GLP toxicity studies, so good laboratory practices studies, in usually two species. So that would be, let's say, mouse and dog, dog and monkey, mouse and monkey, demonstrating the safety of the molecule. Then the FDA may or may not let you start a human clinical trial. Those safety studies are very formal and very expensive. Usually they take you 9 t
2026 BIO International Convention | Insilico Medicine 2026 BIO International Convention Map Your Show DOWNLOAD June 22- 25 San Diego, CA Menu See more links My Planner My Profile Recommendations Sign Out Event Directory Featured Exhibitors Map Sessions and Speakers My Show Planner See more links My Planner My Profile Recommendations Sign Out Sending Email... There are no available appointments for this exhibitor. Saving... Saving... Insilico Medicine Booths Booth Locations Exhibit Hall — 4021 Contact Information About Insilico Medicine Product Categories Research Technology > AI / Machin
Instagram Instagram Log In Sign Up Close Never miss a post from melissa_leich Sign up for Instagram to stay in the loop. Sign up Log in melissa_leich • Follow More options melissa_leich Edited • 5w Three weeks ago Insilico Medicine, an AI-driven biotech, signed one of the most significant AI-pharma deals right now. $2.75 billion with Eli Lilly. Four days ago they announced the industry’s first Longevity Board. Using AI to target the biology of aging itself. Not treat disease. Prevent it. Thursday in Singapore I had a conversation with Alex Zhavoronkov. The founder & CEO behind all of it. T
Drug Target Identification | Insilico Medicine School Course Home Page PandaOmics (demo edition) Login Disease Modeling and Target Discovery Free course for anyone interested in drug discovery and healthcare innovation Enroll for Free About this course Disease modeling and target discovery are critical areas in biomedical research that involve using computational and experimental approaches to gain insights into the causes of diseases and identify potential targets for drug development. With the increasing prevalence of complex diseases such as cancer, Alzheimer's, and diabetes, there is a gro … rends. A special emphasis is placed on case studies to illustrate the practical application of the concepts covered. In particular, course participants have the opportunity to freely explore a demo edition of PandaOmics, a popular commercial tool for target discovery and omics data analysis. Course Trailer Upon completion of the program you will gain: In-depth knowledge of the challenges and opportunities in drug target discovery, including the emerging role of AI, achievemen … genome concept. Exposure to several case studies that illustrate the practical application of the concepts covered, and the ability to critically evaluate and compare different target discovery strategies. Who is the course for? The target audience for this course is individuals interested in drug discovery, biomedical research, and healthcare innovation such as researchers, scientists, and professionals in the pharmaceutical industry. The course is especially suitable for s … ior information from various sources such as publications, clinical trials, and grant applications. The algorithms used by PandaOmics consider multiple factors, including novelty, confidence, commercial tractability, druggability, safety, and other essential properties that influence the selection of therapeutic targets. PandaOmics has been instrumental in identifying new targets for various diseases, including cancer, Amyotrophic Lateral Sclerosis ( ALS), COVID-19, and relat … lliance Manager, AI Platform Frank W. Pun , PhD, MBA, Head of Hong Kong Office, Application Science Lead Alexander Veviorskiy , Sr. Bioinformatician, Target Discovery Anna Gaponova , PhD, Research Biologist Shan Chen , PhD, Associate Director of Bioinformatics Anastasia Shneyderman , PhD, Data Curation Team Lead Vladimir Naumov , MD, Bioinformati
Insilico Medicine Uses Generative AI to Accelerate Drug Discovery | NVIDIA Blog Skip to content Quicker Cures: How Insilico Medicine Uses Generative AI to Accelerate Drug Discovery The startup, a premier member of NVIDIA Inception, is entering Phase 2 clinical trials with a drug candidate discovered using its AI platform. June 27, 2023 by Renee Yao 0 Comments Share Share This Article X Facebook LinkedIn Copy link Link copied! While generative AI is a relatively new household term, drug discovery company Insilico Medicine has been using it for years to develop new therapies for debilitating dis
Podcast 1. Reacting to inSilico AI's AI-discovered drug trials. The Matter Blotter Subscribe Sign in The Matter Blotter Podcast 1. Reacting to inSilico AI's AI-discovered drug trials. 5 3 1× 0:00 Current time: 0:00 / Total time: -5:47 -5:47 Audio playback is not supported on your browser. Please upgrade. Podcast 1. Reacting to inSilico AI's AI-discovered drug trials. AI-discovered drugs and materials start to deliver in the commercial world. Alan Aspuru-Guzik Dec 05, 2021 5 3 Share Hi Matter Blotter readers (and now listeners!) This is my first attempt at creating a simple podcast. I aim
From Start to Phase 1 in 30 Months | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability &n
Pharmaceutical Superintelligen…–FYI - For Your Innovation – Apple Podcasts Search Home New Top Charts Search 10 July 2025 1hr 31min Pharmaceutical Superintelligence With Alex Zhavoronkov FYI - For Your Innovation Play In this episode of FYI, Chief Futurist, Brett Winton, and Analyst Nemo Marjanovic speak with Alex Zhavoronkov, founder and CEO of Insilico Medicine. Together, they explore the promise of artificial intelligence in transforming the drug discovery process—cutting years off timelines and dramatically reducing costs. Alex shares Insilico’s journey from algorithm-first begin
Pathway activation profiling reveals new insights into Age-related Macular Degeneration and provides avenues for therapeutic interventions | Aging Submit an Article Navigate Home Editorial Board Editorial Policies Current Volume Archive Scientific Integrity Publication Ethics Statements Interviews with Outstanding Authors Newsroom Sponsored Conferences Podcast Contact Special Collections Submit an Article Online ISSN: 1945-4589 Navigate Home Editorial Board Editorial Policies Current Volume Archive Scientific Integrity Publication Ethics Statements Interviews with Outstanding Authors Newsroom … ific Meeting of the BSRA NOVA 2026 Recap Longevity & Aging Series 2025 EPIC Award Winner: Longevity & Aging Series Research Paper | Volume 6, Issue 12 | pp 1064 —1075 Pathway activation profiling reveals new insights into Age-related Macular Degeneration and provides avenues for therapeutic interventions Evgeny Makarev 1 Insilico Medicine, Inc, ETC, Johns Hopkins University, Baltimore, MD 21218, USA , Charles Cantor 2 , Boston University, Boston, MA 02215, USA 3 Retro
Qilu inks $120M, AI-enabled cardiometabolic pact with Insilico Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey
Insilico Medicine scores $255M venture round to move AI-designed drugs into human clinical trials | Fierce Biotech Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events
Lilly signs $2.75B deal with Insilico for oral therapeutics Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Ev … es could follow, according to a March 29 release. Under the deal, Insilico will grant Lilly an exclusive worldwide license for the development, manufacturing and commercialization of certain preclinical oral therapeutics for undisclosed indications. The two companies will also partner on R&D for assets selected by Lilly. Cambridge, Massachusetts-based Insilico aims to target diseases with significant unmet need, founder and CEO Alex Zhavoronkov, Ph.D., said in a statement
Deep Knowledge Ventures and Insilico Medicine Enter into a Convertible Bridge Note Agreement to Combat Aging | Fierce Biotech Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fie … NG--( BUSINESS WIRE )--Today Deep Knowledge Ventures, a Hong Kong-based venture fund specializing in early and growth stage investments in Big Data and Life Sciences industries, announced the completion and execution of a milestone-based convertible bridge note agreement with Baltimore-based Insilico Medicine, Inc. The agreement was signed during the JP Morgan conference in San Francisco in mid-January and executed today. According to the terms of the agreement, Deep Knowledg … enable the company to get their capabilities validated by third parties and to submit the vital papers demonstrating the performance of their drug repurposing algorithms. We also recognize Insilico's need to have physical presence in Basel so they can keep closer contact with their Big Pharma partners with local support and management expertise." Deep Knowledge Ventures showcased Insilico Medicine along with its other portfolio companies during the JPMorgan conference in San … on January 28th Insilico received the "Most Promising Company in Healthtech/IT" award at the PMWC2015 congress in Palo Alto, and was selected for the finals of the NVIDIA GPU Technology Challenge out of more than 150 technology companies. For its next round of funding, which will be led by a large European venture capital firm and will include Deep Knowledge Ventures, Insilico Medicine must meet a number of milestones. First, Insilico must demonstrate its ability to conclusiv … ut Deep Knowledge Ventures Deep Knowledge Ventures is a Hong Kong-based venture fund management company focused on deploying machine learning to accelerate progress in high-impact fields. DKV's investment portfolio spans biotechnology, regenerative medicine, oncology, drug discovery, bioinformatics and personalized medicine. For more information,
Feng Ren - Insilico Medicine Ltd | ChinaBio™ Partnering Forum Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. April 28–29, 2026 Kerry Hotel Pudong, Shanghai, China May 6–7, 2026 - Digital Partnering Home home Get involved expand_more Registration Comp
Was a pleasure to host Collin Bantle, a colleague from Insilico Medicine, at our lab after the American Society of Clinical Oncology (ASCO) meeting and show a beautiful UChicago campus. | Evgeny Izumchenko LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
Expanding the Immuno-oncology Toolbox with an AI-discovered Target and Novel Inhibitor | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docutho … - a newly introduced LAG-3 immune checkpoint pathway. In contrast to the narrow application of adoptive T-cell therapy, immunotherapy using checkpoint blockade antibodies has shown promising results across a wide range of cancer types, not only in traditionally immunogenic tumors such as melanoma and renal cell carcinoma, but also in lung cancer, bladder cancer, and head and neck cancer. Yet, the approved checkpoint therapies also brought considerable safety and tolerability
AACR 2023 | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability EN _ 简 _ 繁 Main Abou
Insilico Medicine Showcases Preclinical Breakthroughs for Four AI-Powered Oncology Pipelines at AACR Annual Meeting 2026 Press Releases 2026-04-21 08:00 Insilico Medicine Showcases Preclinical Breakthroughs for Four AI-Powered Oncology Pipelines at AACR Annual Meeting 2026 The 2026 American Association for Cancer Research (AACR) Annual Meeting took place from April 17 to 22 at the San Diego Convention Center in California. As the premier multidisciplinary event in the oncology landscape, AACR serves as a global hub for cutting-edge research, driving innovation across academia and industry thro
Multimodal Transformers and Their Applications in Drug Target Discovery for Aging and Age-Related Diseases Multimodal Transformers and Their Applications in Drug Target Discovery for Aging and Age-Related Diseases J Gerontol A Biol Sci Med Sci . 2024 Sep 1;79(9):glae006. doi: 10.1093/gerona/glae006. Authors Barbara Steurer 1 , Quentin Vanhaelen 1 , Alex Zhavoronkov 1 2 3 Affiliations 1 Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, Hong Kong SAR, China. 2 Insilico Medicine AI Limited, Level 6, Unit 08, Block A,
Instagram Instagram Log In Sign Up Close Never miss a post from futurehealth_initiative Sign up for Instagram to stay in the loop. Sign up Log in futurehealth_initiative • Follow Original audio More options futurehealth_initiative 37w Dr. Alex Zhavoronkov, CEO of Insilico Medicine, joined Hadley Gamble at Abu Dhabi Global Health Week to share how artificial intelligence is unlocking new frontiers in longevity science and therapeutic innovation. Dr. Zhavoronkov explained that AI’s power lies in its ability to identify patterns from vast data sets — linking disease, aging, and frailty. This enab
Instagram Instagram Log In Sign Up Close Never miss a post from investinabudhabi Sign up for Instagram to stay in the loop. Sign up Log in Tags helmabudhabi Tags insilicomedicine agwaabudhabi investinabudhabi and helmabudhabi More options investinabudhabi Verified Edited • 7w AI is no longer an emerging layer in healthcare; it is becoming the engine behind how new therapies are discovered and developed. Insilico Medicine and Eli Lilly have announced a $2.75B AI-driven R&D collaboration, marking a significant step in how global drug discovery is evolving. Through initiatives like HELM, supp
Insilico Medicine inks global R&D collaboration with Lilly | The Pharmaletter Tuesday 2 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Card
Longevity investment bulletin: Mitobridge, Fractyl, Insilico and more Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search HAYA Therapeutics begin … digital innovations to advance personalised health.” Rubedo lands $1.45 million grant Senolytics company Rubedo Life Sciences was awarded a $1.45 million grant from the California Institute for Regenerative Medicine to support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF) targeting senescent lung stem cells. “We are delighted to partner with CIRM and appreciate their recognition of the importance of advancing resea
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Events | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability EN _ 简 _ 繁 Main About M
Insilico Medicine leadership to attend 44th Annual J.P. Morgan Healthcare Conference Press Releases 2026-01-08 21:32 Insilico Medicine leadership to attend 44th Annual J.P. Morgan Healthcare Conference Leadership from Insilico Medicine (“Insilico”, HKEX:03696), a world-leading artificial intelligence (AI)-driven drug discovery company, will attend the 44th Annual J.P. Morgan Healthcare Conference Jan. 12-15, 2026, in San Francisco. Representatives from Insilico Medicine including founder, CEO & CBO Alex Zhavoronkov, PhD will be available throughout the week for one-on-one meetings with inv
BIO International Convention 2023 | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability &nb
Insilico Medicine - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membershi
Joining us as a Longevity... - Longevity Investors Conference Facebook Вход Публикация Longevity Investors Conference Longevity Investors Conference 31 март · Поделился/-ась с Доступно всем Joining us as a Longevity Investors Ambassador - and as a speaker at LIC 2026 in Gstaad. Garri Zmudze is General Partner at LongeVC, co-founder of the Longevity Science Foundation, and one of longevity's most active angel investors - with exits including Insilico Medicine and Deep Longevity. He's been building the longevity ecosystem long before it was on everyone's radar. Link in bio to lear
Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery … s to develop drugs for these indications first, and then expand their potential application to broader aging-related interventions. Insilico Medicine stands at the forefront of this new wave. By leveraging generative AI, Insilico identifies dual-purpose targets positioned at the critical intersection of chronic disease and biological aging. This approach allows the company to develop therapeutics that not only address immediate clinical needs but also modulate the underlying … power that can actually move the needle, " said Michael Levitt, PhD, 2013 Nobel Prize laureate in Chemistry. "Aging is not a single problem — it is a deeply interconnected web of molecular and cellular processes, and only by targeting that complexity systematically, with AI tools sophisticated enough to map it, do we have a realistic chance of extending not just lifespan but healthspan. I am proud to be part of an effort that is serious, scientifically grounded, and ambitious … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Fresh from ARDD | Alex Zhavoronkov LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy … phed into a ”high-signal filter for longevity” - packed with startups (who also fund it), hard data, and mainstream pharma. Alex looks back at his 2014 Nvidia talk (”Can Nvidia solve aging?”) and explains why Insilico trains its AI to learn age first - so it actually grasps biology. Years of problem-solving with pharma turned into their Pharma.AI toolkit. Insilico now runs 40+ programs and in an early Phase 2 study for idiopathic pulmonary fibrosis (IPF), their drug rentosert
ARDD for healthy longevity: How science, technology and investment are redefining the future Press Releases 2025-08-21 05:58 ARDD for healthy longevity: How science, technology and investment are redefining the future Imagine a future where living longer is not only possible but comes with vitality and health. As the world grapples with an aging population, the race to unlock the secrets of longevity has become one of the most dynamic frontiers in science and technology. What’s more covetable than making money? Probably Living longer According to the United Nations' 2022 World Population Prosp
Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery Press Releases 2026-04-21 20:00 Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery CAMBRIDGE, Mass., April 21, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry’s first Longevity Board (Board). The initiative provides scientific oversight and strategic guidance for AI-ena … s to develop drugs for these indications first, and then expand their potential application to broader aging-related interventions. Insilico Medicine stands at the forefront of this new wave. By leveraging generative AI, Insilico identifies dual-purpose targets positioned at the critical intersection of chronic disease and biological aging. This approach allows the company to develop therapeutics that not only address immediate clinical needs but also modulate the underlying … power that can actually move the needle, ”said Michael Levitt, PhD, 2013 Nobel Prize laureate in Chemistry. “Aging is not a single problem — it is a deeply interconnected web of molecular and cellular processes, and only by targeting that complexity systematically, with AI tools sophisticated enough to map it, do we have a realistic chance of extending not just lifespan but healthspan. I am proud to be part of an effort that is serious, scientifically grounded, and ambitious
TD Securities podcast: AI in drug discovery with Insilico Medicine | Insilico Medicine posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … studies and pharmaceutical collaborations that validate the successful clinical application of AI in accelerating drug discovery and repurposing. https://lnkd.in/gWXJ8MMM …more Blueprint: AI and Algorithmic Drug Discovery Pipeline https://www.youtube.com/ 3 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Artelligence Therapeutics 997 followers 7mo Report this post AI Is Redefining Every Step of Drug Discovery At Artelligence Therapeutics, we see
Comments - Podcast 1. Reacting to inSilico AI's AI-discovered drug trials. The Matter Blotter Subscribe Sign in Podcast 1. Reacting to inSilico AI's… Alan Aspuru-Guzik Dec 5, 2021 5 3 AI-discovered drugs and materials start to deliver in the commercial world. Listen → 3 Comments Top first Fred Patton Jun 26, 2022 I don't mind long podcasts, but I found it beneficial to listen to bite-sized podcasts, and the episode details are a nice springboard for further exploration. Thanks for all the valuable content. Reply Share Minhaaj Dec 6, 2021 fascinating work Reply Share Ms Dec 6, 2021 I liked
Docuthon | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability EN _ 简 _ 繁 Main About … Winner Junyue Wang Best Editing Shin Honorable Mention Ekarthaan Studio Special Award The Afghan Dreamers MEET THE JUDGES Dr. Alex Zhavoronkov Founder and CEO of Insilico Medicine Alvaro A. Ricciardelli Spanish/Argentinian journalist, producer, filmmaker and editor Oren Rosenfeld Multi Emmy Award winning Documentary Filmmaker Amelia Martyn-Hemphill Presenter, podcast host and self-shooting filmmaker for the BBC and Fast Company Taryn Southern Award-winning artist, storyteller … outhern Award-winning artist, storyteller and strategist Laila Kazmi Multi Emmy Award winning producer, Sr. Content Manager and Producer at Amazon All the docs capture that in different ways. There is also a sense of "mission" in all the interviews. The story is showing us that there are many positive ways of making AI work in favor of everyone's well being in a world where everyone seems to be talking about AI, and is focusing on its potential risks. Alvaro Alvarez Ricciarde … Southern The most creative and poetic introduction – gave me chills! Multi Emmy Award winning producer, Sr. Content Manager and Producer at Amazon Award-winning artist, storyteller and strategist Spanish/Argentinian journalist, producer, filmmaker and editor Statement → Documentary Director, Editor Excellent use of AI visuals. This piece was well done from all perspectives – technically well executed, thematically clear, well-paced, and beautiful integration of both education … s the transformative potential of AI in the field of drug discovery. Multi Emmy Award winning Documentary Filmmaker Presenter, podcast host and self-shooting filmmaker for the BBC and Fast Company Alvaro Alvarez Ricciardelli We want to impact and enable others", a great focus on sharing knowledge rather than competition. The ending is also very g
#56, Alex Zhavoronkov and the …–AWS Health Innovation Podcast – Apple Podcasts Search Home New Top Charts Search 11 July 2023 46 min #56, Alex Zhavoronkov and the GenAI Revolution in Drug Discovery at Insilico Medicine AWS Health Innovation Podcast Play On the latest episode of the AWS Health Innovation Podcast, Dr. Yin He, Principal Business Development, Healthcare & Life Sciences Startups, welcomes Alex Zhavoronkov, the CEO of Insilico Medicine, to the show for a fascinating conversation about their transformative work at the intersection of AI & BioTech. Insilico Medicine is an end- … ch. We also shed light on the ethical and regulatory challenges surrounding the application of AI for drug development and Insilico's strategies to address them. [03:55] Alex Zhavoronkov background & career journey [09:40] Shift to using computational tools in chemistry [16:40] AI's evolution over time & developing Insilico's core approach [24:20] Ethical and regulatory challenges of using AI for drug development [29:30] Bits meet atoms - automated labs & GenAI [3
AI Revolutionizes Longevity Medicine with Alex Zhavoronkov | Insilico Medicine posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … ins what happens when you build large-scale, full-stack biological datasets and apply advanced AI to uncover what’s been invisible. This is exactly why ChronicleBio exists. Because once we truly understand the biology, we’re going to be able to get to a cure so much faster. This full episode of The Dr. Hyman Show ( Function Health ) is now available at the link below on YouTube or Apple Podcasts and Spotify. Watch: https://lnkd.in/g3mHDmdp 29 Like Comment Share Copy LinkedIn
Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39 - Flot.bio Skip to content Map Episodes Articles Advertise About Us Subscribe Free Map Episodes Articles Advertise About Us Subscribe Free Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39 Youtube Spotify Philip Hemme • Sep 22, 2025 We chat about longevity with Alex Zhavoronkov , CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine . Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year. Alex gives us a tour of I … fore clinical trials. So you do one formal step of existing testing and you can apply for IND and go into phase one. And in 2022, we nominated nine. So it was quite, quite a big jump. Usually even within big pharmaceutical 9, 9, 9. Nine developmental candidates. Okay. So okay. Yeah. In 2022, I think we had one IND. That means that we actually started phase one. And so yeah, so it was then we nominated 22 developmental candidates. So basically starting 2021. Then reached clini
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine - Vibe Bio Skip to content Why AI analytics? VibeOne platform Expand How VibeOne works AI for business development Portfolio Resources Expand Blog Events Media Resource library About us Expand Jobs Contact us Contact us Toggle Menu Home / Podcast / The Future of Aging, AI, and Robotics with CEO of Insilico Medicine The Future of Aging, AI, and Robotics with CEO of Insilico Medicine By Christina Wong September 23, 2024 June 30, 2025 In this episode, VibeCast host Ray Dogum speaks with Alex Zhavoronkov, PhD, founder and CEO of I … of aging and his passion for continuous improvement in health. 00:05:24 – Application of Deep Neural Networks in Biomedical Research Alex delves into the application of deep neural networks in aging research and drug discovery. He highlights the synchronization of biological data types with time and the use of generative adversarial networks for predicting and imagining new molecules with desired properties. 00:08:33 – Overcoming Challenges in AI Adoption in Biote … eptical that it was going to perform really well in biotech. And every time you submit a research publication, you always have to compare with traditional approaches, right? You compare with linear regression, you compare with support vector machines, so more classical forms of machine learning here in k nearest neighbors, and very often those models outperform in domain specific tasks, right? And especially when the data is limited. That’s it. So you have to explain th … 7;t get any slides. I hope not either. Yeah, but At this point in time Once you submit to your application to the FDA to start a human clinical trial, It has to go through very rigorous review. And even if you use some, I don’t know, black magic to come up with a drug and it worked beautifully in many models, but it showed poor safety, they will not give you a good go ahead, right? You would need to prove safety, and preferably to some extent efficacy before you start c … So go ahead, like try to explain some of the oldest drugs. And usually when you submit your application to the FDA with a new targeted therapeutic, you would need to explain the mechanism in a much more rigorous way than most of the drugs that are approved to date, right? And, have been in clinical practice for a long time. Even if you, and most
Instagram Instagram Log In Sign Up Close Never miss a post from avillalonv Sign up for Instagram to stay in the loop. Sign up Log in avillalonv Verified • Follow Original audio More options avillalonv Verified 4d 2016 Alex Zhavoronkov pionero GANs drug discovery. Fundó Insilico Medicine 2014. PhD Física Moscú, maestría Biotecnología Johns Hopkins. Levantó 530+ millones. 22 candidatos preclínicos, 10 fase clínica. Rentosertib Fase IIa fibrosis pulmonar — target y molécula por IA. FDA Orphan Drug Designation. 160+ papers. Top 100 líderes IA healthcare. Clarivate Highly Cited Scientist 2022. #sci
Insights to Innovation: Insilico Medicine AI-driven Practice Published on Springer Nature in Latest AI for Drug Discovery Volume Press Releases 2026-01-19 08:00 Insights to Innovation: Insilico Medicine AI-driven Practice Published on Springer Nature in Latest AI for Drug Discovery Volume Since the late 20th century, the exploration into drug discovery empowered by artificial intelligence has lasted for decades, revealing the promise of AI in complex data integration, de novo molecular design, and clinical translation. Yet, providing solid guidance on exactly how and where these technologies c … n the comprehensive and forward-looking volume, sharing experience in real-life application of AI in early drug target-related tasks including evaluation, and giving prospects for the future assisted with quantum computing. The book has obtained 1700+ accesses, only 10 days after publication. The “ Artificial Intelligence for Drug Target and Pathway Identification, Assessment, Validation, and Indication Expansion ” chapter was led by Alex Zhavoronkov PhD, founder and CEO, CBO … the cycle from theoretical exploration to academic publication, then real-world application, and back to industry-level guide”, said Alex Zhavoronkov PhD, founder and CEO, CBO of Insilico Medicine. “We are providing the roadmap for a transition from traditional R&D to a state of Pharmaceutical Superintelligence (PSI), where AI agents actually make decisions to minimize failure in the clinic. Our mission is far more than just treating symptoms, it is about extending health
Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39 - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Vive la radiorésistance: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and colonization | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Journal Content Home Editorial Board Submission Current Volume Archive Scientific Integrity Editorial Policies Publication Ethics Statements Special Collections Interviews with Outstanding Authors Oncotarget In The News Sponsored Conferences Search Contact Information Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through … fferent fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial , Introducing Oncotarget . As of January 1, 2022, Oncotarget has shifted to a continuous publishing m … joining compared to the homologous recombination [ 29 , 30 , 36 , 200 – 202 ]. Application of the comprehensive multi-omics analytical tools on transcriptomic and proteomic data may serve as another useful approach for the individual radioresistance assessment [ 203 – 206 ]. All the approaches discussed in the next chapters, combined with the initial selection of radioresistant individuals, should significantly empower our ability to protect space mission crew members agains … of exposure to cosmic radiation that spacefaring humans undergo. Indeed, such a proposal could have positive potential implications as a preventative strategy for carcinogenesis in general, regardless of exposure to cosmic irradiation. The above strategy could also potentially be used to attenuate the negative physiological effects of long-term exposure to microgravity when specifically targeted to the constitutive and supportive cells of muscular and osseous tissues. The sec … e studies were partially supported by the Russian Foundation for Basic Research grant #17-29-01002 ofi_m. REFERENCES 1. Chancellor JC, Scott GB, Sutton JP. Space Radiation: The Number One Risk to Astronaut Health beyond Low Earth Orbit. Life (Basel). 2014; 4:491–510. https://doi.org/10.3390/life4030491 . 2. Martinez R, Goodliff KE, Whitley RJ. IS
Media Kit | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability EN _ 简 _ 繁 Main Abou … 400 million in funding. Investors include: Prosperity7 (Aramco's growth venture fund), B Capital Group, Warburg Pincus, BHR Partners, Qiming Ventures, Deerfield, Pavilion Capital, BOLD Capital, Eight Roads, Lilly Asia Ventures, Sinovation Ventures, CPE, OrbiMed, Mirae Asset Capital, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners. Welcome to "Coding the Impossible Cure" a documentary that captures our … search and development Read more Alex Aliper, PhD President Areas of expertise: application of AI for drug discovery and drug repurposing, generative chemistry and generative biology Read more Petrina Kamya, PhD Head of AI Platforms President of Insilico Medicine Canada Harnessing AI for Target Discovery & Drug Design Read more Alex Zhavoronkov, PhD Chairman of the Board, Executive Director and CEO Alex Zhavoronkov, PhD , is the founder and CEO of Insilico Medicine ( insi … arget identification, and signaling pathway modeling. In 2016, he pioneered the application of key technologies in Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) to drug discovery, discovering novel targets and generating novel molecules with satisfied properties. Prior to Insilico, Dr. Zhavoronkov worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroGNeuroinformatics , Biogerontology Research Foundation . Since 2012 h … ident Alex Aliper, PhD, is the President of Insilico Medicine. He pioneered the application of AI in multi-omics data for drug discovery and drug repurposing, generative chemistry and generative biology and put an AI-designed drug into human clinical trials. He built a team of over 100 AI engineers that developed state-of-the-art software product
Insilico appoints co-CEO in readiness for clinical data test Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Mabwell to present positive... P
Stream episode Biotech CEO interview on AI assisted Drug Discovery with Insilico Co-CEO Feng Ren by Citeline podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Biotech CEO interview on AI assisted Drug Discovery with Insilico Co-CEO Feng Ren by Citeline published on 2023-02-23T02:50:58Z Citeline managing editor Brain Yang discusses with Insilico Co-CEO and Head of Drug Discovery Feng Ren on artificial intelligence-assisted drug discovery for idiopathic pulmonary fibrosis. https://scrip.pharma
Insilico Medicine appoints Dr. Feng Ren as co-CEO Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview Tre … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Why I Left Big Pharma for AI: Insilico Medicine’s Co-CEO Dr. Feng Ren| Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sust … ed is really fast," he says, "and I'm looking forward to how we can continue to apply the AI platform to make it even more efficient." Pharma Turns to Insilico's AI Platform Dr. Ren isn't the only pharma veteran taking an interest in AI. Since PandaOmics and Chemistry42 were commercialized during the second half of 2020, numerous pharma companies have licensed Insilico's technology or formed partnerships, including Fosun Pharmaceuticals, PAQ Therapeutics, Huadong Medicine, Ar
Insilico pens potential $888M cancer R&D pact with Servier Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey
Insilico agrees $66M deal to split rights for NLRP3 inhibitor Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey
Lilly will commercialize Insilico's AI-discovered oral drug candidates | STAT Skip to Main Content Manage alerts for this article Email this article Share this article Cancer ASCO research Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home News Latest STAT10 Busines … Artificial intelligence , biotechnology , drug development , Eli Lilly , STAT+ Submit a correction request Reprints Brittany Trang Health Tech Reporter Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter . Follow her on Threads , Mastodon , and Bluesky . You can reach Brittany on Signal at btrang.01. Newsletter Understand how science, health policy, and medicine shape
Insilico strikes gold with Sanofi deal worth up to $1.2B Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Event
Insilico Medicine provides benchmark timelines from its 22 AI-designed drug candidates Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Pod
AI drug designer Insilico Medicine aims for $300M in Hong Kong IPO Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Su … , B Capital Group, Prosperity7, OrbiMed, Deerfield, Pavilion Capital, PIDC, CPE fund, Mirae Asset Capital, Lilly Asia Ventures, Eight Roads, Lake Bleu Capital, Baidu Ventures and Sinovation Ventures. Its $110 million series E round this year was led by the Hong Kong-based firm Value Partners. Insilico Medicine IPO Hong Kong drug discovery Artificial Intelligence AI and Machine Learning MedTech Connect The Team Advertise Marketing Kit Let's Talk Join Us Newsletters Resour
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI September 18, 2024 | 7 min read Twitter LinkedIn Facebook Email Print ISM001-055 is a novel drug designed in-house using generativ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Insilico: linking target discovery and generative chemistry AI platforms for a drug discovery breakthrough Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement View all journals Search Log in Content Explore content About the journal Sign up for alerts RSS feed nature biopharma dealm … ning in biopharma has come of age. After working for years to understand how to apply an artificial intelligence (AI) approach to biotechnology, Insilico Medicine recently disclosed the discovery of a novel drug target and novel molecule using AI. The discovery, a world first, took less than 18 months and cost 10% as much as a conventional program. Having validated its platforms, Insilico is now making the technology available to big pharmaceutical companies. Insilico was fou … I, biology and chemistry experts rose to that challenge and established ways to apply deep learning to biotech through the publication of more than 120 peer-reviewed papers in academic journals and at top AI conferences. The work culminated in establishing interconnected deep learning models and advanced AI approaches capable of delivering a preclinical drug candidate in under 18 months for just over $2 million. Validating breakthrough AI platforms Insilico validated its AI p … ave drug-like molecular structures and suitable physicochemical properties. The application of Chemistry42 to the novel target revealed by PandaOmics led to the generation of a library of small molecules. Multiple molecules showed promising on-target inhibition, with one hit achieving nanomolar IC50 values without showing any sign of CYP inhibition. Optimization of that hit, named ISM001, improved solubility and resulted in good ADME properties. Subsequent studies found the m … at least two of these programs into human clinical trials inventing new ways to apply AI to improve both enrollment and monitoring of clinical trials. However, while focusing on internal development, Insilico also made its target discovery platforms, PandaOmics and Chemistry42 available for the other companies to substantially improve their drug
Insilico Medicine - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 History 2 International operations Toggle International operations subsection 2.1 Canada 2.2 Hong Kong 2.3 Russia 2.4 United Arab Emirates 3 Research 4 See also 5 References 6 External links Toggle the … The Russian subsidiary of Insilico also became one of the largest recipients of grant funding from the Skolkovo Foundation. According to publicly available grant data, the company's project dedicated to applying the iPANDA signaling pathway analysis algorithm and deep learning methods to omics data for drug discovery received a grant of 89.99 million rubles, placing it among the ten largest grant recipients of the foundation. [ 45 ] [ 46 ] After the Russian in … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Insilico Medicine 3 lan
Main | Insilico Medicine Product of interest PandaOmics PandaOmics Box Chemistry42 Generative Biologics Science42:DORA inClinico I agree to Privacy Policy Required Field Please enter a valid email address Please enter a valid name Please enter a valid phone number Value is too small Send Request Required Field Please enter a valid email address Please enter a valid name Please enter a valid phone number Value is too small Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 … essor, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. He touches on OPUS-X and AlphaFold and how each contribution has advanc
Insilico Medicine | | The Pharmaletter Wednesday 3 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene Therap … e-powered pharmacological analysis platform. In 2016, Zhavoronkov pioneered the application of Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) technologies to drug discovery, marking a watershed moment in the company's evolution. Since inception, Insilico has achieved multiple historic milestones, including nominating 11 preclinical candidates, advancing programs into human clinical trials, and raising over $400 million across multiple funding roun … ectual basis for AI-powered pharmacological analysis. Zhavoronkov pioneered the application of Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) to drug discovery in 2016, marking a pivotal moment in computational therapeutics. He has published over 200 peer-reviewed research articles and authored three books on artificial intelligence and drug discovery. Zhavoronkov was recognized among the top 100 AI leaders in drug discovery by Deep Knowledge Analytics
Charles Cantor - Advisor at Insilico Medicine | The Org Platform Enrich Pricing Log in Sign up Insilico Medicine Charles Cantor Unverified Charles Cantor Advisor Contact No bio yet Org chart View org chart This person is not in the org chart Teams View all teams Advisory Services 8 people, 0 jobs Offices View all offices This person is not in any offices Related people Matthias Aydt Faraday Future Jeff Nelson Linden Capital Partners Rich Ellinger Cota Capital Christian Catalini Lightspark Kristin Fine ClearGov Ben K. Arctop View more Company About Contact Blog Business Solutions Trust Pricin
The Former Head of the Human Genome Project Joins InSilico --> Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthca
PCC | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability EN _ 简 _ 繁 Main About Miss … ata generated at each step of the drug discovery process, making it a lucrative application for modern AI technologies. The application of such technologies has been shown to be beneficial at pretty much every step of the drug discovery process — especially at the hypothesis generation and target identification stage. Deep learning models and natural language processing technologies are compelling when modeling large complex multi-dimensional data sets, such as genomics, prot
Team | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers Docuthon PreciousGPT Sustainability EN _ 简 _ 繁 Main About Mis … arget identification, and signaling pathway modeling. In 2016, he pioneered the application of key technologies in Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) to drug discovery, discovering novel targets and generating novel molecules with satisfied properties. Prior to Insilico, Dr. Zhavoronkov worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroGNeuroinformatics , Biogerontology Research Foundation . Since 2012 h … ident Alex Aliper, PhD, is the President of Insilico Medicine. He pioneered the application of AI in multi-omics data for drug discovery and drug repurposing, generative chemistry and generative biology and put an AI-designed drug into human clinical trials. He built a team of over 100 AI engineers that developed state-of-the-art software products for target discovery, small molecule generation and clinical trial outcome prediction, and he has published over 50 peer-reviewed … s drugs. Michael Levitt, PhD Professor, Stanford University Winner of the Nobel Prize in Chemistry (2013) Michael Levitt is a Nobel Prize-winning biophysicist who has conducted pioneering work on the molecular structure of essential biological compounds. He has made many significant contributions to the study of protein folding and helped to popularise the use of computer modelling in biology. Amongst the foremost of Michael's numerous scientific achievements is his developme … has received many honours and awards for his research, including the 2013 Nobel Prize in Chemistry and the 2014 DeLano Award for Computational Biosciences. A member of the US National Academy of Sciences, since 1987 he has been a Professor of Structural Biology at Stanford University. Dr. Kai-Fu Lee Chairman and CEO, Sinovation Ventures President